Literature DB >> 32092274

Facile Construction of i-Motif DNA-Conjugated Gold Nanostars as Near-Infrared and pH Dual-Responsive Targeted Drug Delivery Systems for Combined Cancer Therapy.

Dandan Miao1, Yanyan Yu1, Yong Chen1, Yin Liu2, Gaoxing Su1.   

Abstract

Stimuli-responsive DNA-based nanostructures have emerged as promising vehicles for intelligent drug delivery. In this study, i-motif DNA-conjugated gold nanostars (GNSs) were fabricated in a facile manner as stimuli-responsive drug delivery systems (denoted as A-GNS/DNA/DOX) for the treatment of cancer via combined chemo-photothermal therapy. The i-motif DNA is sensitive to the environmental pH and can switch from a single-stranded structure to a C-tetrad (i-motif) structure as the environmental pH decreases from neutral (∼7.4) to acidic (<6.0). The loaded drug can then be released along with the conformational changes. To enhance cellular uptake and improve cancer cell selectivity, the aptamer AS1411, which recognizes nucleolins, was employed as a targeting moiety. The A-GNS/DNA/DOX nanocomposites were found to be highly capable of photothermal conversion and exhibited photostability under near-infrared (NIR) irradiation, and the pH and NIR irradiation effectively triggered the drug-release behaviors. In addition, the A-GNS/DNA/DOX nanocomposites exhibited good biocompatibility. The targeting recognition enabled the A-GNS/DNA/DOX to exhibit higher cellular uptake and therapeutic efficiency than the GNS/DNA/DOX. Notably, under NIR irradiation, a synergistic effect between chemotherapy and photothermal therapy can be achieved with the proposed delivery system, which exhibits much higher therapeutic efficiency both in monolayer cancer cells and tumor spheroids as compared with a single therapeutic method. This study highlights the potential of GNS/DNA nanoassemblies for intelligent anticancer drug delivery and combined cancer therapy.

Entities:  

Keywords:  DNA nanostructures; cancer therapy; combined therapy; drug delivery; gold nanostars; stimuli-responsive

Mesh:

Substances:

Year:  2020        PMID: 32092274     DOI: 10.1021/acs.molpharmaceut.9b01159

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Prospects and challenges of dynamic DNA nanostructures in biomedical applications.

Authors:  Taoran Tian; Yanjing Li; Yunfeng Lin
Journal:  Bone Res       Date:  2022-05-23       Impact factor: 13.362

Review 2.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

Review 3.  Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment.

Authors:  Gengqi Liu; Jonathan F Lovell; Lei Zhang; Yumiao Zhang
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

4.  A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy.

Authors:  Liyu Zhang; Meng Wang; Zeen Zhu; Chenxi Ding; Shengquan Chen; Haibin Wu; Ying Yang; Fengyu Che; Qiao Li; Hui Li
Journal:  Int J Nanomedicine       Date:  2021-05-10

5.  Probing the Intracellular Bio-Nano Interface in Different Cell Lines with Gold Nanostars.

Authors:  Cecilia Spedalieri; Gergo Péter Szekeres; Stephan Werner; Peter Guttmann; Janina Kneipp
Journal:  Nanomaterials (Basel)       Date:  2021-04-30       Impact factor: 5.076

Review 6.  Application of microneedle patches for drug delivery; doorstep to novel therapies.

Authors:  Fateme Nazary Abrbekoh; Leila Salimi; Sepideh Saghati; Hassan Amini; Sonia Fathi Karkan; Keyvan Moharamzadeh; Emel Sokullu; Reza Rahbarghazi
Journal:  J Tissue Eng       Date:  2022-04-29       Impact factor: 7.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.